GUANGZHOU, China -- A Chinese startup that provides cancer risk diagnosis and other services is showing rapid growth as the country's aging population, shocked by the novel coronavirus, is beginning to take its health more seriously.
Genetron Health, whose kits offer more gene-analysis reagents than competitors' products, is generating wide-ranging demand as Chinese grow increasingly aware of the importance of early detection in the treatment of cancer.
